Skip to main content

Table 1 Overview of treatments administered to the different experimental groups

From: Liposomal doxorubicin improves radiotherapy response in hypoxic prostate cancer xenografts

Experimental groups Treatment
Control No treatment
PL-DXR 3.5 mg DXR/kg (day 0)
PL-DXR + hypoxic RT 3.5 mg DXR/kg (day 0) + clamping + 2 Gy/day for 5 days (day 1 - day 5)
RT 2 Gy/day for 5 days (day 1 - day 5)
Hypoxic RT Clamping + 2 Gy/day for 5 days (day 1 - day 5)